COVID-19 Related – Therapeutics for Improving Lung Function

Impaired mucous clearance occurs in patients with a variety of conditions. Patients with non-congenital defects such as neuromuscular weakness, anatomic weakness, asthma, and immunodeficiency can all suffer from recurrent pneumonia due to impaired mucous clearance or mucous stasis. One example of a disease with defects in mucociliary clearance is cystic fibrosis (CF). CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). UAB researchers discovered that the compound ivacaftor (VX-770), a CFTR activator, enhances mucociliary transport in normal primary human bronchial epithelial cells. Ivacaftor or other similar CFTR activators could therefore be used as therapeutics for the treatment of patients with non-congenital defects that result in impaired mucociliary clearance. Karen Bernard kbernard@uab.edu (205) 934-8826

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More